Publications

The Breast

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

Using PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.

November 2020

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.

November 2020

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.

May 2020

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.

May 2020

Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.

April 2020

Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.

February 2020

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.

January 2020

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.

December 2019

ASCO-GU 2021 VIRTUAL

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza)

• Simultaneous profiling of Androgen Receptor splicing variants, hotspot mutations and amplifications at both cfDNA and cfRNA levels.

February 2021

Publications

The Breast

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

Blood

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

European Urology

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

European Urology

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

EBioMedicine

Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Chinese Journal of Cancer Research

Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

Critical Reviews in Oncology

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

BREAST CANCER RESEARCH

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Posters

ASCO-GU 2021 VIRTUAL

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza)

ASCO-GU 2021 VIRTUAL

Superior molecular pathology of urothelial bladder cancer using urinary cell-free DNA

ASCO-GU 2021 VIRTUAL

Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study

ASCO-GU 2021 VIRTUAL

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts

ASCO-GI 2021 VIRTUAL

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

SABCS 2020 VIRTUAL

Germline Mutation Landscape in Chinese Breast Cancer Patients

SITC 2020 Virtual

Development and validation of blood tumor mutational burden reference standards

ASCO 2020 Virtual

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)

AACR - Advances in Liquid Biopsies 2020

Simultaneous Multi-parametric Profiling of cfRNA and ctDNA in Advanced-stage Colorectal Cancer

AACR 2020 Virtual

Development of cfDNA-based methylation assay for early cancer detection

AACR 2020 Virtual

Urine-based molecular biomarker signatures for bladder cancer

AACR 2020 Virtual

Combined cell-free DNA and cell-free RNA NGS testing for cancer patient care

ASCO 2020 Virtual

Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China

ASCO-GU 2020

Biomarker Analysis (CTC and ctDNA/ctRNA) of GT0918 (Proxalutamide) New AR Blocker in Phase I mCRPC Patients with Dose Escalation

ASCO-GU 2019

Plasma-based Exploratory Biomarker Analysis to Evaluate GT0918 in a Phase 1/2 Study in mCRPC Patients

Abstracts

2019 SABCS

Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance

2019 SABCS

Blood-based detection of PTEN loss and pathway alterations for personalized treatment of breast cancer

2019 SABCS

Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA

2019 ASCO

Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival

2019 AACR

Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy response

2019 AACR

Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients

2019 AACR

Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in immuno-oncology

2019 ASCO-GU

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer

2018 SABCS

Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients

Get in touch